cysteamine has been researched along with Parkinsonian Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alpaugh, M; Chen, X; Cicchetti, F; David, LS; Durcan, T; Lauinger, N; Saint-Pierre, M; Siddu, A | 1 |
| Badrinarayanan, S; Boivin, L; Bousquet, M; Chabrat, A; Charest, J; Cicchetti, F; Cisbani, G; Drouin-Ouellet, J; Gibrat, C; Lagacé, M; Lavallée-Bourget, MH; Lebel, M; Lévesque, M; Saint-Pierre, M | 1 |
| Chan, P; Sun, L; Wang, C; Wu, Y; Xu, S; Zhou, M | 1 |
3 other study(ies) available for cysteamine and Parkinsonian Disorders
| Article | Year |
|---|---|
Beneficial effects of cysteamine in Thy1-α-Syn mice and induced pluripotent stem cells with a SNCA gene triplication.
Topics: alpha-Synuclein; Animals; Cysteamine; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Locomotion; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinsonian Disorders | 2020 |
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Indans; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurites; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders | 2015 |
Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cysteamine; Disease Models, Animal; Dopamine; Glutathione; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Reactive Oxygen Species; Substantia Nigra; Treatment Outcome | 2010 |